Pharmaceutical intermediates
Rotigotine Intermediates
5 pharmaceutical intermediates for Rotigotine. Indication: Restless legs syndrome; Parkinson's disease.
About Rotigotine
- Originator
- Ucb Inc.
- Indication
- Restless legs syndrome; Parkinson's disease
- Approved Date
- 04/02/2012
- DS/DP
- 11/27/2025
Available intermediates
5 intermediates currently listed for Rotigotine. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Methoxy-2-tetralone | 32940-15-1 | / | / |
| (S)-2-AMINO-5-METHOXYTETRALIN HYDROCHLORIDE | 105086-80-4 | / | / |
| (S)-2-Amino-5-methoxytetralin Hydrochloride | 58349-17-0 | / | / |
| (S)-1,2,3,4-Tetrahydro-5-methoxy-N-propyl-2-naphthalenamine hydrochloride | 93601-86-6 | / | / |
| (S)-2-Amino-5-methoxytetralin (S)-mandelate | 439133-67-2 | / | / |
Other programs under R
Building toward Rotigotine?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →